Macquarie Updated GXY to Neutral, page-45

First 45 Last

Share
Profile

Follow
Alterego1168

1,525 Posts.

17

14/04/17

00:36

Post #: 24071856
Share

Originally posted by Endyne ↑

And these predictions argue to not to be bullish on lithium and particularly GXY because?

Same FUD oversupply argument.

Where is the price crash and catastrophic destruction of the value proposition of GXY? Where is it categorically not a $1b++ company with 2-3 producing assets in 3-4 years time selling at those prices?

The funny thing is that all of those analysts are already wrong about pricing for 2017 - except Deutsche which is predicting the price to be basically that which GXY is about to sell for. (Job well done!) Morgan Stanley and Dundee are not even in the right solar system, let alone ballpark, with those figures (from 6-12 months ago I might add).

The variation and period of those predictions tells me what I already know, that know one really has any certainty as to where the price of lithium will be in 5 years. No one can even predict the price of iron ore or coal with any accuracy over 12 months!

So say then price does go back to $US600/t in a couple of years. Company will still be very profitable.

Your sentiment doesn't match the evidence used to support it.

No point DYOR if your not going to accept what you discover, think critically for yourself and act accordingly.

Expand

Who said anything about price crash.

It's also Deutsche that is predicting a price depreciation
Mathew Hocking is from Deutsche and as you've said it yourself, Deutsche is got it right. He's right here in Sydney.
He's right here in Sydney, and obviously closest to the "action".

GXY Price at posting: 42.5¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

RBA holds rates as ALP election campaigning kicks off – expect more political focus

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

RCE

Recce reaches key dosing milestone in testing of skin infection gel

HVN

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate